Lung Cancer Diagnosis
Lung Cancer Diagnosis
A clear answer in days, not months — and it is not just about naming the disease. Diagnosis decides which treatments can work for you, so the tests matter as much as the result.
Step 1: Imaging — finding it and mapping it
Everything begins with pictures. Which scan you need depends on whether we are screening a person at risk, investigating a symptom, or mapping a known tumor.
The screening test. It detects nodules smaller than a fingernail, years before symptoms, and uses only a modest radiation dose — far less than a conventional CT. For people at higher risk it is the single most effective way to find lung cancer while cure is still likely.
Shows the nodule's exact size, shape and density, and whether lymph nodes in the chest are enlarged. This is the scan that decides whether a nodule looks stable, suspicious, or clearly requires tissue sampling.
A whole-body scan that shows metabolic activity — how "hungry" the tissue is. It helps tell a benign scar from an active tumor, and reveals whether the disease has spread to lymph nodes, bone, liver or elsewhere. Both scanners are in-house at our hospitals, so there is no outsourcing delay.
Added when the tumor type or stage makes spread to the brain a realistic possibility, since the brain is a common site of spread that CT does not assess well.
Step 2: Tissue — confirming it is cancer
Imaging can raise suspicion, but only tissue proves it. A biopsy also gives us the material every later decision depends on.
Bronchoscopy
A thin, flexible scope passes through the mouth and airway, under light sedation. It reaches tumors near the centre of the lung and can sample lymph nodes at the same time using ultrasound guidance (EBUS) — often the most efficient single test when glands are involved.
CT-guided needle biopsy
For tumors near the outer edge of the lung, a fine needle is guided through the chest wall under CT, with local anesthetic. It takes about 30 minutes; you may feel pressure rather than pain, and you are observed afterwards to check for complications such as a small collapsed lung.
Step 3: Pathology — what kind of lung cancer is it
Lung cancer is not one disease. Two families behave very differently, and the distinction changes treatment from the first day:
Non-small cell lung cancer (NSCLC)
About 85% of cases. The common subtypes are adenocarcinoma (most frequent, often in the outer lung, and common in never-smokers), squamous cell carcinoma (usually near the central airways), and large cell carcinoma. NSCLC is the group where surgery, radiosurgery, targeted drugs and immunotherapy all play major roles.
Small cell lung cancer (SCLC)
Less common, faster-growing and more likely to have spread by the time it is found. It is treated mainly with chemotherapy and radiotherapy, with immunotherapy added in many cases. Because it behaves so differently, identifying it correctly is essential.
Pathology also reports how the tumor looks under the microscope and whether surgical margins are clear in removed specimens — details that later guide both treatment and follow-up.
Step 4: Molecular profiling — what is driving the cancer
For NSCLC, we test the tumor's genetics because a targeted drug only works when its target is present. This is where precision oncology actually begins.
These alterations are more common in East Asian patients, particularly in never-smokers. If one is present, a matching oral targeted drug can control the disease with fewer side effects than chemotherapy.
Measures a protein that predicts how likely you are to respond to immunotherapy. It is read alongside the mutation results, not instead of them.
Tests many genes at once from a single tissue sample, and can also be done from a blood sample (liquid biopsy) when tissue is limited or a repeat biopsy is not practical.
Step 5: Staging — how far has it gone
Staging summarises the tumor's size and local extent (T), lymph node involvement (N), and spread to distant organs (M). In plain terms:
| Stage | What it means | Typical treatment direction |
|---|---|---|
| Stage I | Small tumor confined to the lung, no node involvement | Surgery, or radiosurgery when surgery is not suitable — both with cure as the aim |
| Stage II | Larger tumor, or cancer in nearby lymph nodes on the same side | Surgery, usually with additional drug therapy; radiosurgery in selected cases |
| Stage III | Locally advanced — tumor involving central structures or nodes on both sides of the chest | Combined treatment: chemotherapy with radiation or immunotherapy, sometimes followed by surgery |
| Stage IV | Cancer has spread beyond the chest | Targeted therapy, immunotherapy or chemotherapy; radiotherapy and interventional treatments for control of specific sites |
Stage is not the only deciding factor. We also score your lung function and general fitness, because the most effective treatment is only useful if your body can tolerate it — and because protecting your breathing capacity is part of the goal, not a secondary concern.
See how each stage is treated for what these options involve in practice.
From diagnosis to a plan
When the results are in, they are not handed to a single department. Thoracic surgery, medical oncology, radiation oncology, interventional radiology, radiology and pathology review your case together and issue one unified plan — because when surgery, radiosurgery, targeted therapy and immunotherapy are all reasonable options, the choice should be made by collective judgement rather than departmental habit.
- CT, MRI and PET-CT images (DICOM files if available) or their written reports
- Pathology and biopsy reports, including the tumor type and any molecular results
- Laboratory results, including tumor markers and liver or kidney function
- A list of treatments already received and how the tumor responded
- A short summary of your main symptoms and when they started
With complete records, the panel's unified plan is returned within 48 hours.